Atypical antipsychotic medications in the management of disruptive behaviors in children: Safety guidelines and recommendations

Clinical Psychology Review

Volumn 31, Issue 3, 2011, Pages 465-471

  McKinney, Cliff ^a   Renk, Kimberly ^b  

^a MISSISSIPPI STATE UNIVERSITY   (United States)

^b UNIVERSITY OF CENTRAL FLORIDA   (United States)

Author keywords

Adolescent; Atypical antipsychotic medication; Children; Disruptive behavior

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; OLANZAPINE; PLACEBO; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ADOLESCENT; AKATHISIA; AUTISM; BIPOLAR I DISORDER; CHILD; CONDUCT DISORDER; CONSTIPATION; DISRUPTIVE BEHAVIOR; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG FATALITY; DRUG MECHANISM; DRUG SAFETY; DYSLIPIDEMIA; DYSTONIA; EDEMA; EDUCATIONAL STATUS; EPISTAXIS; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; GASTROINTESTINAL HEMORRHAGE; HEADACHE; HEART ARREST; HUMAN; HYPERACTIVITY; HYPERGLYCEMIA; HYPERPROLACTINEMIA; HYPERSALIVATION; HYPERTHYROIDISM; INCREASED APPETITE; IRRITABILITY; LETHARGY; LOW DRUG DOSE; MANIA; MIXED MANIA AND DEPRESSION; NAUSEA; NAUSEA AND VOMITING; NEUROLEPTIC MALIGNANT SYNDROME; PEER GROUP; PENIS ERECTION; PROBLEM SOLVING; PROLACTIN BLOOD LEVEL; PSYCHOTHERAPY; QT PROLONGATION; RECREATION; REVIEW; RHINITIS; SCHIZOPHRENIA; SEDATION; SEXUAL DYSFUNCTION; SIDE EFFECT; SOMNOLENCE; STEREOTYPY; TACHYCARDIA; TREATMENT OUTCOME; TREMOR; UPPER RESPIRATORY TRACT INFECTION; WEIGHT GAIN; XEROSTOMIA;

ADOLESCENT; ANTIPSYCHOTIC AGENTS; ATTENTION DEFICIT AND DISRUPTIVE BEHAVIOR DISORDERS; BENZODIAZEPINES; CHILD; HUMANS; PIPERAZINES; PRACTICE GUIDELINES AS TOPIC; QUINOLONES; RISPERIDONE; TREATMENT OUTCOME;

EID: 79952249925     PISSN: 02727358     EISSN: 18737811     Source Type: Journal    
DOI: 10.1016/j.cpr.2010.11.005     Document Type: Review

References (44)

1. Akdag S.T., Fettahoglu E.C., Ozatalay E. Pedal edema induced by low-dose risperidone monotherapy in a child. Journal of Child and Adolescent Psychopharmacology 2009, 19:481-482.
2. Caldwell M.F., Malterer M., Umstead D., McCormick D.J. A retrospective evaluation of adjunctive risperidone treatment in severely behaviorally disordered boys receiving psychosocial treatment. Journal of Child and Adolescent Psychopharmacology 2008, 18:34-43.
3. Correll C.U., Kane J.M. One-year incidence rates of tardive dyskinesia in children and adolescents treated with second-generation antipsychotics: A systematic review. Journal of Child and Adolescent Psychopharmacology 2007, 17:647-655.
4. Coskun M., Mukaddes N.M. Possible risperidone-related gastrointestinal bleeding or epistaxis in two pediatric cases. Journal of Child and Adolescent Psychopharmacology 2008, 18:299-300.
5. Croarkin P.E., Emslie G.J., Mayes T.L. Neuroleptic malignant syndrome associated with atypical antipsychotics in pediatric patients: A review of published cases. Journal of Clinical Psychiatry 2008, 69:1157-1165.
6. Croonenberghs J., Fegert J.M., Findling R.L., De Smedt G., Van Dongen S. Risperidone in children with Disruptive Behavior Disorders and subaverage intelligence: A 1-year, open-label study of 504 patients. Journal of the American Academy of Child and Adolescent Psychiatry 2005, 44:64-72. the Risperidone Disruptive Behavior Study Group.
7. De Deyn P.P., Buitelaar J. Risperidone in the management of agitation and aggression associated with psychiatric disorders. European Psychiatry 2006, 21:21-28.
8. Elbe D. Commentary to QTc prolongation associated with atypical antipsychotic use in the treatment of adolescent-onset Anorexia Nervosa. Journal of the Canadian Academy of Child and Adolescent Psychiatry 2009, 18:64.
9. Eldevik S., Hastings R.P., Hughes J.C., Jahr E., Eikeseth S., Cross S. Meta-analysis of early intensive behavioral intervention for children with autism. Journal of Clinical Child and Adolescent Psychology 2009, 38:439-450.
10. Erdogan A., Atasoy N., Akkurt H., Ozturk D., Karaahmet E., Yalug I., et al. Risperidone and liver function tests in children and adolescents: A short-term prospective study. Progress in Neuropsychopharmacology and Biological Psychiatry 2008, 32:849-857.
11. Findling R. Dosing of atypical antipsychotics in children and adolescents. Primary Care Companion Journal of Clinical Psychiatry 2003, 5:10-13.
12. Findling R.L., Aman R.G., Eerdekens M., Derivan A., Lyons B. Long-term, open-label study of risperidone in children with severe disruptive behaviors and below-average IQ. American Journal of Psychiatry 2004, 161:677-684.
13. Fraguas D., Merchan-Naranjo J., Laita P., Parallada M., Moreno D., Ruiz-Sancho A., et al. Metabolic and hormonal side effects in children and adolescents treated with second-generation antipsychotics. Journal of Clinical Psychiatry 2008, 69:1166-1175.
14. Frick P.J., Cornell A.H., Bodin S.D., Dane H.E., Barry C.T., Loney B.R. Callous-unemotional traits and developmental pathways to severe conduct problems. Developmental Psychology 2003, 39:246-260.
15. Frick P.J., O'Brien B.S., Wootton J.M., McBurnett K. Psychopathy and conduct problems in children. Journal of Abnormal Psychology 1994, 103:700-707.
16. Greenaway M., Elbe D. Focus on aripiprazole: A review of its use in child and adolescent psychiatry. Journal of the Canadian Academy of Child and Adolescent Psychiatry 2009, 18:250-260.
17. Haas M., Karcher K., Pandina G.J. Treating Disruptive Behavior Disorders with risperidone: A 1-year, open-label safety study in children and adolescents. Journal of Child and Adolescent Psychopharmacology 2008, 18:337-346.
18. Halperin J.M., Kalmar J.H., Schulz K.P., Marks D.J., Sharma V., Newcorn J.H. Elevated childhood serotonergic function protects against adolescent aggression in disruptive boys. Journal of the American Academy of Child and Adolescent Psychiatry 2006, 45:833-840.
19. Handen B.L., Gilchrist R. Practitioner review: Psychopharmacology in children and adolescents with mental retardation. Journal of Child Psychology and Psychiatry 2006, 47:871-882.
20. Handen B.L., Hardan A.Y. Open-label, prospective trail of olanzapine in adolescents with subaverage intelligence and Disruptive Behavior Disorders. Journal of the American Academy of Child and Adolescent Psychiatry 2006, 45:928-935.
21. Hazell L., Shakir S.A. Under-reporting of adverse drug reactions: A systematic review. Drug Safety 2006, 29:385-396.
22. Janowsky D.S., Shetty M., Barnhill J., Elamir B., Davis J.M. Serotonergic antidepressant effects on aggressive, self-injurious and destructive/disruptive behaviours in intellectually disabled adults: A retrospective, open-label naturalistic trial. International Journal of Neuropsychopharmacology 2004, 8:37-48.
23. Kazdin A.E. Conduct Disorder in childhood and adolescence 1995, Sage, Newbury Park, CA. 2nd ed.
24. Kazdin A.E. Psychosocial treatments for conduct disorder in children and adolescents. A guide to treatments that work 2007, 71-104. Oxford University Press, New York, NY. 3rd ed. P.E. Nathan, J.M. Gorman (Eds.).
25. Masi G., Milone A., Canepa G., Millepiedi S., Mucci M., Muratori F. Olanzapine treatment in adolescents with severe conduct disorder. European Psychiatry 2006, 21:51-57.
26. Mehler-Wex C., Romanos M., Kirchheiner J., Schulze U.M.E. Atypical antipsychotics in severe Anorexia Nervosa in children and adolescents: Review and case reports. European Eating Disorders Review 2008, 16:100-108.
27. McKinney C., Renk K. Emerging research and theory in the etiology of Oppositional Defiant Disorder: Current concerns and future directions. International Journal of Behavioral Consultation and Therapy 2007, 3:349-371.
28. Miller C.M. Regulation sought for foster kids prescribed psychiatric drugs. Miami Herald May, 2010, Retrieved from http://www.miamiherald.com/2010/03/02/1507445/regulations-sought-for-foster.html.
29. Neuhut R., Lindenmayer J.P., Silva R. Neuroleptic malignant syndrome in children and adolescents on atypical antipsychotic medication: A review. Journal of Child and Adolescent Psychopharmacology 2009, 19:415-422.
30. Olfson M., Blanco C., Liu L., Moreno C., Laje G. National trends in the outpatient treatment of children and adolescents with antipsychotic drugs. Archives of General Psychiatry 2006, 63:679-685.
31. Ray W.A., Chung C.P., Murray K.T., Hall K., Stein C. Atypical antipsychotic drugs and the risk of sudden cardiac death. New England Journal of Medicine 2009, 360:225-235.
32. Research Units on Pediatric Psychopharmacology Autism Network Risperidone treatment of autistic disorder: Longer-term benefits and blinded discontinuation after 6months. American Journal of Psychiatry 2005, 162:1361-1369.
33. Rey, J. M., & Walter, G. (1999). Oppositional defiant disorder. In R. L. Hendren (Series Ed.), J. M. Oldham & M. B. Riba (Vol. Eds.), Review of psychiatry: Vol. 18. Disruptive Behavior Disorders in children and adolescents (pp. 99-132). Washington, DC: American Psychiatric Press, Inc.
34. Reyes M., Buitelaar J., Toren P., Augustyns I., Eerdekens M. A randomized, double-blind, placebo-controlled study of risperidone maintenance treatment in children and adolescents with Disruptive Behavior Disorders. American Journal of Psychiatry 2006, 163:402-410.
35. Reyes M., Olah R., Csaba K., Augustyns I., Eerdekens M. Long-term safety and efficacy of risperidone in children with Disruptive Behavior Disorders. European Child and Adolescent Psychiatry 2006, 15:97-104.
36. Ritchie B., Norris M.L. QTc prolongation associated with atypical antipsychotic use the treatment of adolescent-onset Anorexia Nervosa. Journal of the Canadian Academy of Child and Adolescent Psychiatry 2009, 18:60-63.
37. Scott L.J., Dhillon S. Spotlight on risperidone in irritability associated with Autistic Disorder in children and adolescents. CNS Drugs 2008, 22:259-262.
38. Sivaprasad L., Hassan T., Handy S. Survey of atypical antipsychotic medication use by child and adolescent psychiatrists. Child and Adolescent Mental Health 2006, 11:164-167.
39. Staller J.A., Wade M.J., Baker M. Current prescribing patterns in outpatient child and adolescent psychiatric practice in central New York. Journal of Child and Adolescent Psychopharmacology 2005, 15:57-61.
40. Stigler K.A., McDougle C.J. Pharmacotherapy of irritability in Pervasive Developmental Disorders. Child and Adolescent Psychiatric Clinics of North America 2008, 17:739-752.
41. Troost P.W., Lahuis B.E., Steenhuis M.P., Ketelaars C.E.J., Buitelaar J.K., Van Engeland, et al. Long-term effects of risperidone in children with autism spectrum disorders: A placebo discontinuation study. Journal of the American Academy of Child and Adolescent Psychiatry 2005, 44:1137-1144.
42. Wadoo O., Chalhoub N. Risperidone-induced sexual dysfunction in a prepubertal child: A case report. Journal of Psychopharmacology 2009, 23:727-728.
43. Zito J.M., Derivan A.T., Kratochvil C.J., Safer D.J., Fegert J.M., Greenhill L.L. Off-label psychopharmacologic prescribing for children: History supports close clinical monitoring. Child and Adolescent Psychiatry and Mental Health 2008, 2:24.
44. Zito J.M., Safer D.J., Jong-van den Berg L.T.W., Janhsen K., Fegert J.M., Glaeske G., et al. A three-country comparison of psychotropic medication prevalence in youth. Child and Adolescent Psychiatry and Mental Health 2008, 2:26.